BRBrazil
Dr Reddy's wins ANVISA approval for generic semaglutide in Brazil and names Aché as launch partner
Brazil's regulator ANVISA approved Dr Reddy's generic semaglutide for adults with type 2 diabetes, and the Indian company will launch with Aché. It gave no date or price, and other generics are already in the market.
Illustration by Peptide Global, not a picture of the place in the story.
The short of itBrazil's regulator ANVISA approved Dr Reddy's generic semaglutide injection for adults with type 2 diabetes, and the Indian company will launch it with Aché at an undisclosed date and price.
Dr Reddy's Laboratories has won approval to sell generic semaglutide in Brazil for adults with type 2 diabetes, the Hyderabad company said on 5 November. ANVISA, the Brazilian health regulator, granted the marketing authorization, and Dr Reddy's plans to launch through a partnership with the Brazilian drugmaker Aché. The company gave no launch date, price or sales target. It follows a slow start for the company's semaglutide in India, where a manufacturing problem held up its launch this year.
What ANVISA approved
The authorization covers a weekly semaglutide injection for adults whose type 2 diabetes is not controlled well enough, used together with diet and exercise, according to company statements reported by Medical Dialogues and RTTNews. It may be prescribed on its own when metformin cannot be used because of intolerance or contraindications, or alongside other diabetes medicines. That matches the diabetes use of Ozempic, the Novo Nordisk brand it copies, and does not include weight management, which in Novo's range is sold as Wegovy. Dr Reddy's said it will supply the drug in a prefilled pen that holds several weekly doses, in two presentations. The approval sits with ANVISA, while the price ceiling a new medicine can charge in Brazil is set separately by the national drug market regulator.
Dr Reddy's leaned on two market figures in its announcement. Brazil has about 16.6 million adults aged 20 to 79 living with diabetes, which the company said makes it the sixth largest country by that count. It also estimated the semaglutide market for diabetes in Brazil at about 244.6 million US dollars, without naming a year or a data provider. MV Ramana, the chief executive of the company's global generics business, said its aim with semaglutide is to widen access in markets where many patients need the treatment, according to the reports. An investor round-up on ad-hoc-news.de noted that the approval itself fixes no launch date and no sales contribution.
Generic semaglutide in Brazil is filling up
Brazil was one of the first big markets where copies of semaglutide became possible, because the main Novo Nordisk patent there has lapsed, as the semaglutide patent expiry map on this site set out in October. That opened the door to local and foreign makers at the same time. The Brazilian company EMS already holds an ANVISA-approved pen made in Sao Paulo state, Reuters reported in May. Another Indian maker, Torrent Pharmaceuticals, has told investors it hopes to launch generic semaglutide in Brazil within six to nine months, though it has not said who will make the product, as our report on the Torrent Brazil launch plan explained.
Generic semaglutide in Brazil therefore means a contest among several suppliers rather than a single cheap copy.
Generic semaglutide in Brazil therefore means a contest among several suppliers rather than a single cheap copy. Dr Reddy's brings a Brazilian partner in Aché and its own experience of selling the drug in India, but it arrives after EMS and alongside other Indian entrants. Retail price and pharmacy reach are likely to decide how much of the market each copy wins, since the products are the same molecule for the same diabetes use. None of the companies has published a Brazilian price for its semaglutide, so any claim about the size of discounts against Ozempic would be a guess at this stage.
| Item | Detail | Source |
|---|---|---|
| Regulator | ANVISA, Brazil | Company statement |
| Date announced | 5 November 2026 | Company statement |
| Approved use | Adults with insufficiently controlled type 2 diabetes, with diet and exercise | Company statement |
| Format | Prefilled multidose pen for weekly use, two presentations | Company statement |
| Launch partner | Aché | Company statement |
| Adults with diabetes in Brazil | About 16.6 million, aged 20 to 79 | Company statement |
| Company estimate of the diabetes semaglutide market | About 244.6 million US dollars | Company statement |
| Launch date and price | Not disclosed | Company statement |
Why the India supply story matters here
Brazilian partners and inspectors will look closely at where the product is made, because Dr Reddy's had trouble at home this year. In India the company had to pause its semaglutide plans after an impurity appeared when it scaled up production, and its restart depended on three validation batches, as Peptide Global reported in October. The company later told investors that a relaunch in India in November was at the top of its recovery plan, after a fall in quarterly profit. The Brazilian approval does not say which plant will supply the product or whether it uses the same ingredient source as the Indian launch. Those details matter to ANVISA inspections and to Aché, which will carry the commercial risk of any supply gap.
Supply reliability is also the one area where a late entrant can win share from earlier ones. Peptide drugs need long, carefully controlled production runs, and a maker that cannot keep pharmacies stocked loses prescribers quickly. If Dr Reddy's can show steady output from India while serving both its home market and Brazil, its approval becomes a meaningful source of generic semaglutide in Brazil. If the Indian restart slips again, the Brazilian launch could be delayed as well. The company has not linked the two timelines in public, and it has not said whether the Brazilian product will come from the same lines that make semaglutide for India.
What to watch next
The first marker is a launch date from Aché or Dr Reddy's, together with the price that the national drug market regulator allows. The second is whether the company files a weight management version, which would compete with Wegovy rather than Ozempic and reach a much larger self-pay market. Dr Reddy's has not said whether it plans such a filing in Brazil. The third is the response from Novo Nordisk, which still sells Ozempic and Wegovy in Brazil and has been pushing its newer products elsewhere, including its Wegovy tablet. A move by Novo on price in Brazil would show how seriously it takes the generic wave.
The last marker is the wider field. Brazil already has a local copy from EMS, Torrent has a stated plan, and Dr Reddy's holds an approval with a named partner. For patients the practical change will come only when pens are on pharmacy shelves at prices below the brand, and that has not happened yet for this product. For the Indian industry, Brazil has become a test of whether the generic semaglutide model built at home can work abroad, and Dr Reddy's will be judged by how quickly it turns this paper approval into steady supply. Its next quarterly update is the natural place for that answer.
Conclusion
Dr Reddy's has added Brazil to its semaglutide plan with an ANVISA approval for type 2 diabetes and a launch partner in Aché, but no date or price yet. Generic semaglutide in Brazil is now a contest among several makers, and the outcome will depend on price, pharmacy reach and steady supply from India. Watch for the launch date, the regulated price ceiling and any weight management filing.
Why it matters in Brazil
The main semaglutide patent has lapsed in Brazil, where about 16.6 million adults live with diabetes. Dr Reddy's joins EMS and a planned Torrent launch, so price and steady supply will decide who wins share from Ozempic.
What to watch
The launch date and the price ceiling set for the product, any weight management filing, and whether Dr Reddy's Indian semaglutide restart stays on track.
Sources
Spotted a wrong figure? Tell the desk; we fix errors under our corrections policy.
Peptide Global reports news about medicines and markets. Nothing here is medical or investment advice.